No Data
Kunming Shipbuilding Intelligence: Report for the first quarter of 2025
Kunming Shipbuilding Intelligence: 2024 Annual Report
Kunchuan Intelligence: 2024 Annual Report Summary
Kunshan Asia Vets (301311.SZ): Net income of 6.4015 million yuan in 2024, a decrease of 92.05% year-on-year.
On April 20th, Gelonghui reported that Kunshan Intelligent Manufacturing (301311.SZ) released its annual report for 2024. In 2024, the company insists on deeply implementing the "three wins" principle, focusing on marketing work for the "Intelligent Manufacturing and Smart Logistics" industry, strengthening the technical team, and delving into industries such as Tobacco, Wine, Energy, and Pharmaceuticals to meet diverse customer needs, while continuing to expand market share in related industries. Additionally, a technical team is being formed to break through challenges and further enhance product competitiveness. During the reporting period, revenue reached 2.002 billion yuan, a year-on-year decrease of 4.04%, and the Net income attributable to shareholders of the listed company was 6.
Kunshan Asia Vets (301311.SZ) reported first quarter results, with a net loss attributable to shareholders of 15.7523 million yuan, turning from profit to loss.
Kunshan Asia Vets (301311.SZ) released the Q1 2025 report, and the company has...
Kunshan Asia Vets (301311.SZ): The impact of the recent domestic increased tariffs on the company's existing Business is limited.
On April 8, Gelonghui reported that Kunshan Asia Vets (301311.SZ) announced that recently, the USA government issued a so-called "reciprocal tariff" policy, imposing higher tariffs, which has attracted high market attention. Kunshan Asia Vets Technology Co., Ltd. (hereinafter referred to as "the company"), as a publicly listed company controlled by a state-owned enterprise, actively responds to calls from its actual controller and continuously pays close attention to Global trade policies. After preliminary assessment, the impacts of the increased tariffs by the USA on the company and the relevant countermeasures are as follows: In recent years, the company has taken a series of measures to continuously strengthen R&D investment and vigorously develop domestic alternatives, with only some components procured from.
